JP2011520853A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520853A5
JP2011520853A5 JP2011508991A JP2011508991A JP2011520853A5 JP 2011520853 A5 JP2011520853 A5 JP 2011520853A5 JP 2011508991 A JP2011508991 A JP 2011508991A JP 2011508991 A JP2011508991 A JP 2011508991A JP 2011520853 A5 JP2011520853 A5 JP 2011520853A5
Authority
JP
Japan
Prior art keywords
compound according
pharmaceutically acceptable
diluent
carrier
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011508991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520853A (ja
JP4837800B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2008/001647 external-priority patent/WO2009138707A1/en
Publication of JP2011520853A publication Critical patent/JP2011520853A/ja
Publication of JP2011520853A5 publication Critical patent/JP2011520853A5/ja
Application granted granted Critical
Publication of JP4837800B2 publication Critical patent/JP4837800B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011508991A 2008-05-13 2008-05-13 ムスカリンm3受容体アンタゴニストとしてのキヌクリジン誘導体 Expired - Fee Related JP4837800B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2008/001647 WO2009138707A1 (en) 2008-05-13 2008-05-13 Quinuclidine derivatives as muscarinic m3 receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011146438A Division JP2011195593A (ja) 2011-06-30 2011-06-30 ムスカリンm3受容体アンタゴニストとしてのキヌクリジン誘導体

Publications (3)

Publication Number Publication Date
JP2011520853A JP2011520853A (ja) 2011-07-21
JP2011520853A5 true JP2011520853A5 (enExample) 2011-09-29
JP4837800B2 JP4837800B2 (ja) 2011-12-14

Family

ID=40361403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508991A Expired - Fee Related JP4837800B2 (ja) 2008-05-13 2008-05-13 ムスカリンm3受容体アンタゴニストとしてのキヌクリジン誘導体

Country Status (17)

Country Link
US (2) US8329729B2 (enExample)
EP (1) EP2300464A1 (enExample)
JP (1) JP4837800B2 (enExample)
CN (1) CN102089304A (enExample)
AU (1) AU2008356409B2 (enExample)
BR (1) BRPI0822693A2 (enExample)
CA (1) CA2723981A1 (enExample)
CL (1) CL2009001137A1 (enExample)
EA (1) EA017627B1 (enExample)
EC (1) ECSP10010606A (enExample)
HN (1) HN2010002403A (enExample)
IL (1) IL209126A0 (enExample)
MX (1) MX2010012189A (enExample)
NI (1) NI201000195A (enExample)
NZ (1) NZ589091A (enExample)
WO (1) WO2009138707A1 (enExample)
ZA (1) ZA201007988B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807670A (en) * 1995-08-14 1998-09-15 Abbott Laboratories Detection of hepatitis GB virus genotypes
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
US8329729B2 (en) 2008-05-13 2012-12-11 Astrazeneca Ab Quinuclidine derivatives as muscarinic M3 receptor antagonists
EP2315589A4 (en) * 2008-05-13 2013-09-11 Astrazeneca Ab PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A beta2-ADRENOCEPTOR AGONIST
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
CN103265478B (zh) * 2013-05-20 2015-09-30 中国人民解放军第二军医大学 巯基烟酸类化合物及其制备方法
CN114716380B (zh) * 2022-04-01 2024-06-21 新乡医学院 一种相转移催化的4-取代吡唑酮类化合物不对称氟化方法
WO2025171311A1 (en) * 2024-02-09 2025-08-14 University Of Florida Research Foundation, Incorporated Aryl and pyridyl amide pesticides and compositions thereof

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62140C (enExample) * 1942-12-16
DE2104179C3 (de) 1971-01-29 1980-10-02 Knoll Ag, 6700 Ludwigshafen exo-2-Phenyl-bicyclo- [2,2,1] -heptan-2- (N-methylpiperidol-4)-carbonsäureester und dessen Salze, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel
FR2155927A1 (en) 1971-10-15 1973-05-25 Synthelabo 1-phenylcyclo hexane carboxylic acid esters - with antispasmodic and anticholinergic activity
FR2168881A1 (en) 1972-01-25 1973-09-07 Synthelabo Tropanol 1-phenylcycloalkane carboxylic ester salts - spasmolytics and cholinergics
FR2208649A1 (en) 1972-12-01 1974-06-28 Synthelabo 1-(2-Thienyl)cycloalkane carboxylic ester salts - with spasmolytic and anticholinergic activity
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9003057D0 (sv) 1990-09-26 1990-09-26 Astra Ab New process
EE9900034A (et) 1996-07-29 1999-08-16 Pharmacia & Upjohn Ab Arüültsükloalkaankarboksüülestrid, nende kasutamine, farmatseutilised kompositsioonid ja valmistamine
SI0937041T1 (en) 1996-11-11 2003-10-31 Christian R. Noe Use of a pharmaceutically acceptable salt of (3R,2'R)-3-((Cyclopently-hydroxyphenylacetyl)oxy)-1,1-dimethyl-pyrrolidinium for the preparation of a medicament
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
SI1353919T1 (sl) 2000-12-28 2006-12-31 Almirall Prodesfarma Ag Novi derivati kinuklidina in medicinske zmesi, kijih vsebujejo.
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
CA2443346A1 (en) * 2001-04-03 2002-12-05 Aryx Therapeutics Anticholinergic compounds and methods of use
AR033290A1 (es) 2001-04-30 2003-12-10 Glaxo Group Ltd Derivados antiinflamatorios de androstano
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
DE10216333A1 (de) 2002-04-13 2003-10-30 Boehringer Ingelheim Pharma Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
MXPA05003866A (es) 2002-10-11 2005-06-22 Pfizer Derivados de indol como agonistas beta-2.
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
PE20050231A1 (es) 2003-06-24 2005-05-20 Novartis Ag Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
US20090246281A1 (en) 2003-11-03 2009-10-01 Norton Healthcare Ltd. Soft steroid compositions for use in dry powder inhalers
EP1785421A1 (en) 2004-08-30 2007-05-16 Ono Pharmaceutical Co., Ltd. Tropan compound
WO2006035303A1 (en) 2004-09-29 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2006046916A1 (en) 2004-10-29 2006-05-04 Astrazeneca Ab Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428416D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
TW200722418A (en) 2005-04-20 2007-06-16 Astrazeneca Ab Novel compounds
CN101233107A (zh) 2005-08-01 2008-07-30 阿斯利康(瑞典)有限公司 作为趋化因子受体调节剂用于治疗呼吸系统疾病的新哌啶衍生物
TW200738635A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
RU2442771C2 (ru) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Производные бицикло[2,2,1]гепт-7-иламина и их применения
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
JP2009519310A (ja) 2005-12-16 2009-05-14 アージェンタ ディスカバリー リミテッド 環状アミン誘導体およびそれらの使用
EP2013172A4 (en) 2006-04-24 2010-08-04 Astrazeneca Ab NEW ALKYLESTERS FROM CYCLIC AMINO ALCOHOLS WITH MUSCARIN M3 RECEPTORANTAGONOSTIC ACTIVITY FOR THE TREATMENT OF CHRONIC BRONCHIA SUPPRESSION, ASTHMA OR OVERACTIVE HARNBASE
MX2009000475A (es) 2006-07-19 2009-07-10 Astrazeneca Ab Nuevos compuestos de espiropiperidina triciclicos, su sintesis y sus usos como moduladores de la actividad de los receptores de quimioquinas.
GB0702384D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
WO2008023157A1 (en) 2006-08-21 2008-02-28 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as m3-receptor modulators
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008059239A1 (en) 2006-11-14 2008-05-22 Astrazeneca Ab Novel compounds 514
WO2008075006A1 (en) 2006-12-19 2008-06-26 Astrazeneca Ab Piperldinum compounds for treatment of obstructive pulmonary diseases ( copd)
KR20090094460A (ko) 2006-12-19 2009-09-07 아스트라제네카 아베 무스카린 수용체 길항제로서 퀴누클리디놀 유도체
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
WO2008096094A1 (en) 2007-02-06 2008-08-14 Argenta Discovery Ltd. Bicyclor[2.2.1]hept-7-ylamine derivatives as muscarinic m3 receptor modulators
WO2008096093A1 (en) 2007-02-06 2008-08-14 Argenta Discovery Ltd. Oxazole and thiazole derivatives and their uses
GB0702385D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
US7846955B2 (en) 2007-02-07 2010-12-07 Astrazeneca Ab Salt
GB0702382D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New salt
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702416D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
GB0702414D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Oxazole and thiazole derivatives and their uses 2
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
US20100056565A1 (en) 2007-02-15 2010-03-04 Argenta Discovery Limited Heterocyclic Derivatives as M3 Muscarinic Receptors
GB0704000D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
WO2008149053A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Ltd. Bicycl0 [2. 2. 1] he pt- 2-ylamine derivates and their use
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
WO2009098455A1 (en) 2008-02-06 2009-08-13 Astrazeneca Ab 2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease
WO2009098453A1 (en) 2008-02-06 2009-08-13 Astrazeneca Ab Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists
CN102083839B (zh) 2008-02-06 2014-03-26 阿斯利康(瑞典)有限公司 化合物
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
US8329729B2 (en) 2008-05-13 2012-12-11 Astrazeneca Ab Quinuclidine derivatives as muscarinic M3 receptor antagonists
EP2315589A4 (en) 2008-05-13 2013-09-11 Astrazeneca Ab PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A beta2-ADRENOCEPTOR AGONIST
GB0808709D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
GB0808707D0 (en) 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
GB0811100D0 (en) 2008-06-17 2008-07-23 Astrazeneca Ab New combination
GB0811099D0 (en) 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
WO2009153536A1 (en) 2008-06-17 2009-12-23 Argenta Discovery Limited 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
WO2010018352A1 (en) 2008-08-12 2010-02-18 Argenta Discovery Limited Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
GB0814728D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
MX2011001577A (es) 2008-08-12 2011-05-02 Pulmagen Therapeutics Synergy Sal de 2-hidroxi-etansulfonato.
GB0814729D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination

Similar Documents

Publication Publication Date Title
JP2011524896A5 (enExample)
JP2006517939A5 (enExample)
CA2568566A1 (en) Combinations comprising antimuscarinic agents and pde4 inhibitors
JP2010513478A5 (enExample)
JP2007533686A5 (enExample)
JP2017528503A5 (enExample)
JP2008500988A5 (enExample)
JP2017528507A5 (enExample)
WO2008057802A3 (en) Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
JP2010522227A5 (enExample)
JP2013523764A5 (enExample)
JP2017504611A5 (enExample)
JP2008500990A5 (enExample)
JP2013542247A5 (enExample)
JP2014502641A5 (enExample)
JP2009523760A5 (enExample)
WO2008067399A3 (en) Controlled-release multi-layer formulation of piperazine-piperidine antagonists and agonists of the 5-th1a receptor having enhanced intestinal dissolution
JP2009541443A5 (enExample)
WO2007127196A3 (en) DIALKYLPHENYL COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2009050198A3 (en) Combination comprising purine derivatives and other compounds and the use thereof for the treatment of inflammatory and obstructive airway diseases
JP2010522756A5 (enExample)
JP2016534088A5 (enExample)
SI2419104T1 (en) Combinations of 5-HT4 receptor agonists and acetylcholinesterase inhibitors for the treatment of cognitive disorders
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
JP2015514739A5 (enExample)